Oral bioavailability and first-pass effects

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1329-1336

  Kwan, K C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; BILIARY EXCRETION; BIOAVAILABILITY; BIOTRANSFORMATION; DRUG ABSORPTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RELIABILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD CIRCULATION; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 0031452488     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. P. A. Harris and S. Riegelman: Influence of the route of administration on the area under the plasma concentration-time curve. J. Pharm. Sci. 58, 71-75 (1969).
2. M. Gibaldi and S. Feldman: Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve. J. Pharm. Sci. 58, 1477-1480 (1969).
3. R. N. Boyes, H. J. Adams, and B. R. Duce: Oral absorption and disposition kinetics of lidocaine hydrochloride in dogs. J. Pharmacol. Exp. Ther. 174, 1-8 (1970).
4. M. Gibaldi, R. N. Boyes, and S. Feldman: Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci. 60, 1338-1340 (1971).
5. T. Suzuki, Y. Saitok, S. Isozaki, and R. Ishida: Drug absorption and metabolism studies by use of portal vein infusion in the rat. I. Pyloric vein cannulation and its application to study of first-pass effect on bioavailability of propranolol. Chem. Pharm. Bull. 20, 2731-2735 (1972).
6. M. Gibaldi and S. Feldman: Route of administration and drug metabolism. Eur. J. Pharmacol. 19, 523-329 (1972).
7. M. Rowland: Influence of route of administration on drug availability. J. Pharm. Sci. 61, 70-74 (1972).
8. D. Perrier, M. Gibaldi, and R. N. Boyes: Prediction of systemic availability from plasma-level data after oral administration. J. Pharm. Pharmac. 25, 256-257 (1973).
9. T. Suzuki, S. Isozaki, R. Ishida, Y. Satoh, and F. Nakagawa: Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol. Chem. Pharm. Bull. 22, 1639-1645 (1974).
10. M. Gibaldi and D. Perrier: Route of administration and drug disposition. Drug Metab. Rev. 3, 185-199 (1974).
11. C. F. George, E. Q. Blackwell, and D. S. Davies: Metabolism of isoprenaline in the intestine. J. Pharm. Pharmac. 26, 265-267 (1974).
12. W. L. Chiou: Quantitation of hepatic and pulmonary first-pass effect and its implications in pharmacokinetic study. I. Pharmacokinetics of chloroform in man. J. Pharmacokin. Biopharm. 3, 193-201 (1975).
13. K. Iwamoto and C. D. Klaassen: First-pass effect of morphine in rats. J. Pharmacol. Exp. Ther. 200, 236-244 (1977).
14. K. Iwamoto and C. D. Klaassen: First-pass effect of nalorphine in rats. J. Pharmacol. Exp. Ther. 203, 365-376 (1977).
15. K. S. Pang and J. R. Gillette: Theoretical relationships between area under the curve and route of administration of drugs and their precursors for evaluating sites and pathways of metabolism. J. Pharm. Sci. 67, 703-704 (1978).
16. K. S. Pang and J. R. Gillette: A theoretical examination of the effects of gut wall metabolism, hepatic elimination and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow. J. Pharmacokin. Biopharm. 6, 355-367 (1978).
17. W. A. Colbum and M. Gibaldi: Pharmacokinetic model of presystemic metabolism. Drug Metab. Dispos. 6, 193-196 (1978).
18. W. Colburn: A pharmacokinetic model to differentiate preabsorption, gut epithelial, and hepatic first-pass metabolism. J. Pharmacokin. Biopharm. 4, 407-415 (1979).
19. M. K. Cassidy and J. B. Houston: In vivo assessment of extrahepatic conjugation metabolism in first pass effects using the model compound phenol. J. Pharm. Pharmac. 32, 57-59 (1980).
20. K. F. Ilett, C. T. Dollery, and D. S. Davies: Isoprenaline conjugation: a "true first-pass effect" in the dog intestine. J. Pharm. Pharmac. 32, 362 (1980).
21. T. Suzaki, S. Isozaki, T. Ohkuma, and T. Rikihisa: Influence of the route of administration on the mean hepatic extraction ratio of propranolol in the rat. J. Pharm. Dyn. 3, 603-611 (1980).
22. C. F. George: Drug metabolism by the gastrointestinal mucosa. Clin. Pharmacokinet. 6, 259-274 (1981).
23. T. Suzuki, T. Ohkuma, and S. Isozaki: Nonlinear first-pass metabolism of propranolol in the rat. J. Pharm. Dyn. 4, 131-141 (1981).
24. J. Shibasaki, R. Konishi, M. Koike, A. Imamura, and M. Sueyasu: Some quantitative evaluation of first-pass metabolism of salicylamide in rabbit and rat. J. Pharm. Dyn. 4, 91-100 (1981).
25. R. F. Minchin and K. F. Ilett: Presystemic elimination of drugs: theoretical considerations for quantifying the relative contribution of gut and liver. J. Pharm. Sci. 71, 458-460 (1982).
26. C. F. George, D. G. Shand, and A. G. Renwick, eds.: "Presystemic Drug Elimination," Butterworth Scientific, London, 1982.
27. P. J. M. Klippert and J. Noordhoek: Influence of administration route and blood sampling site on the area under the curve. Drug Metab. Dispos. 11, 62-66 (1983).
28. P. J. M. Klippert and J. Noordhoek: The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs. Drug Metab. Dispos. 13, 97-101 (1985).
29. L. M. Tremaine, G. L. Diamond, and A. J. Quebbemann: Quantitative determination of organ contribution to excretory metabolism. J. Pharmacol. Meth. 13, 9-35 (1985).
30. M. V. St-Pierre, X. Xu, and K. S. Pang: Primary, secondary, and tertiary metabolite kinetics. J. Pharmacokin. Biopharm. 16, 493-527 (1988).
31. M. Weiss: Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction. Clin. Pharmacokinet. 18, 419-422 (1990).
32. C. Y. Wu, L. Z. Benet, M. F. Hebert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporin. Clin. Pharmacol. Ther. 58, 492-497 (1995).
33. J. R. Gillette: Sequential organ first-pass effects: simple methods for constructing compartmental pharmacokinetic models from physiological models of drug disposition by several organs. J. Pharm. Sci. 71, 673-677 (1982).
34. W. L. Chiou: Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J. Pharmacokin. Biopharm. 5, 527-536 (1979).
35. W. L. Chiou: The physiological significance of total body clearance in pharmacokinetics studies. J. Clin. Hosp. Pharmacy 7, 25-30 (1982).
36. M. L. Katz and E. N. Bergman: Simultaneous measurements of hepatic and portal venous blood flow in the sheep and dog. Am. J. Physiol. 216, 946-952 (1969).
37. L. A. Bauer, T. O'Sullivan, W. G. Reiss, J. R. Horn, K. Opheim, D. E. Strandness, and R. L. Carithers: Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. Br. J. Clin. Pharmac. 37, 375-381 (1994).
38. J. Burggraaf, H. C. Shoemaker, J. M. Kroon, L. Huisman, C. Kluft, and A. F. Cohen: Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects. Clin. Sci. 86, 497-503 (1994).
39. B. Davis and T. Morris: Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095 (1993).
40. S. Hwang, K. C. Kwan, and K. S. Albert: A linear model of reversible metabolism and its application to bioavailability assessment. J. Pharmacokin. Biopharm. 9, 693-709 (1981).
41. M. Gibaldi: "Biopharmaceutics and Clinical Pharmacokinetics," pp. 24-32, Lea & Febiger. Philadelphia, 1991.
42. M. Rowland and T. N. Tozer: "Clinical Pharmacokinetics: Concepts and Applications," 3rd ed., pp. 119-126, Williams & Wilkins, Baltimore, 1995.
43. P. Macheras, C. Reppas, and J. B. Dressman: "Biopharmaceutics of Orally Administered Drugs," pp. 89-149, Ellis Horwood, London, 1995.
44. K. Hartiala: Metabolism of hormones, drugs, and other substances by the gut. Physiol. Rev. 53, 496-534 (1973).
45. R. M. Welch, J. Cavallito, and A. Loh: Effect of exposure to cigarette smoke on the metabolism of benzo[a]pyrene and acetophenetidin by lung and intestine of rats. Toxicol. Appl. Pharmacol. 23, 749-758 (1972).
46. J. C. Kolars, P. L. Stetson, B. D. Rush, M. J. Ruwart, P. Schmiedlin-Ren, E. A. Duell, J. J. Voorhees, and P. B. Watkins: Cyclosporin metabolism by P450IIIA in rat enterocytes: another determinant of oral bioavailability? Transplantation 53, 596-602 (1992).
47. P. G. Traber, J. Chianale, R. Florence, K. Kim, E. Wojcik, and J. J. Gumucio: Expression of cytochrome P450b and P450e genes in small intestinal mucosa of rats following treatment with phenobarbital, polyhalogenated biphenyls, and organochlorine pesticides. J. Biol. Chem. 263, 9449-9455 (1988).
48. S. K. Gupta, A. Bakran, R. W. G. Johnson, M. Rowland: Cyclosporin-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol. 27, 475-481 (1991).
49. 2α in the human pulmonary circulation. Thorax 31, 713-719 (1976).
50. 1 in the human pulmonary system. Surgery 81, 716-722 (1977).
51. E. Jähnchen, H. Bechtold, W. Kasper, F. Kersting, H. Just, J. Heykants, and T. Meinertz: Lorcainide. I. Saturable presystemic elimination. Clin. Pharmacol. Ther. 26, 187-195 (1979).
52. J. M. Collins and R. L. Dedrick: Contribution of lungs to total body clearance: linear and nonlinear effects. J. Pharm. Sci. 71, 66-70 (1982).
53. M. K. Cassidy and J. B. Houston: In vivo capacity of hepatic and extrahepatic enzymes to conjugate phenol. Drug Metab. Dispos. 12, 619-624 (1984).
54. M. Mistry and J. B. Houston: Quantitation of extrahepatic metabolism. Pulmonary and intestinal conjugation of naphthol. Drug Metab. Dispos. 13, 740-745 (1985).
55. R. Mehvar: Relationship of apparent systemic clearance to individual organ clearances: effect of pulmonary clearance and site of drug administration and measurement. Pharm. Res. 8, 306-312 (1991).
56. A. A. Raoof, P. F. Augustijns, and R. K. Verbeek: In vivo assessment of intestinal, hepatic and pulmonary first pass metabolism of propofol in the rat. Pharm. Res. 13, 891-895 (1996).
57. M. R. Uhing and R. E. Kimura: Active transport of 3-O-methyl-glucose by the small intestine in chronically catheterized rats. J. Clin. Invest. 95, 2799-2805 (1995).
58. K. Tabata, K. Yamaoka, T. Fukuyama, and T. Nakagawa: Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm. Res. 12, 880-883 (1995).
59. D. J. Hoffman, T. Seifert, A. Borre, and H. H. Nellars: Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe of portal blood sampling. Pharm. Res. 12, 889-894 (1995).
60. Y. Kwon and P. B. Innskeep: Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drug. Pharm. Res. 13, 566-569 (1996).
61. K. Tabota, K. Yamaoka, T. Fukuyama, and T. Nakagawa: Local absorption kinetics into the portal system using the portal-venous concentration difference after an oral dose of diclofenac in the awakening rat. Drug Metab. Dispos. 24, 216-220 (1996).